The action of nitric oxide to enhance cell survival in chick cardiomyocytes is mediated through a cGMP and ERK1/2 pathway while p38 mitogen-activated protein kinase-dependent pathways do not alter cell death

Experimental Physiology

Volumn 93, Issue 7, 2008, Pages 834-842

  Rabkin, Simon W ^a   Tsang, Michael Y C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYLTHIAZOL 2 YL) 2,5 DIPHENYL TETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BROMINE DERIVATIVE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHICK; CHICK EMBRYO; CONTROLLED STUDY; HEART MUSCLE CELL; HEART PROTECTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 46149088507     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.042176     Document Type: Article

References (72)

1. Akiyama K, Kimura A, Suzuki H, Takeyama Y, Gluckman TL, Terhakopian A, Katagiri T, Suh KY, Roseto J & Bing RJ (1998). Production of oxidative products of nitric oxide in infarcted human heart. J Am Coll Cardiol 32, 373 379.
2. Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA & Bishopric NH (2001). Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 88, 305 312.
3. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R & Ping P (2002). Mitochondrial PKCε and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCε-MAPK interactions and differential MAPK activation in PKCε-induced cardioprotection. Circ Res 90, 390 397.
4. Barancik M, Htun P, Strohm C, Kilian S & Schaper W (2000). Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol 35, 474 483.
5. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD & Willette RN (2001). Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104, 1292 1298.
6. Bernabe JC, Tejedo JR, Rincon P, Cahuana GM, Ramirez R, Sobrino F & Bedoya FJ (2001). Sodium nitroprusside-induced mitochondrial apoptotic events in insulin-secreting RINm5F cells are associated with MAP kinases activation. Exp Cell Res 269, 222 229.
7. Bueno OF & Molkentin JD (2002). Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91, 776 781.
8. Cary SP, Winger JA, Derbyshire ER & Marletta MA (2006). Nitric oxide signaling: no longer simply on or off. Trends Biochem Sci 31, 231 239.
9. Chae HJ, So HS, Chae SW, Park JS, Kim MS, Oh JM, Chung YT, Yang SH, Jeong ET, Kim HM, Park RK & Kim HR (2001). Sodium nitroprusside induces apoptosis of H9C2 cardiac muscle cells in a c-Jun N-terminal kinase-dependent manner. Int Immunopharmacol 1, 967 978.
10. Choi BM, Pae HO, Jang SI, Kim YM & Chung HT (2002). Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol 35, 116 126.
11. Dudley DT, Pang L, Decker SJ, Bridges AJ & Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92, 7686 7689.
12. Engel S, Yan L, Weiss H & Scholz P (2001). Negative functional effects of cGMP mediated by cGMP protein kinase are reduced in T4 cardiac myocytes. Eur J Pharmacol 421, 23 30.
13. English JM & Cobb MH (2002). Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23, 40 45.
14. Fernandez PA, Rotello RJ, Rangini Z, Doupe A, Drexler HC & Yuan J (1994). Expression of a specific marker of avian programmed cell death in both apoptosis and necrosis. Proc Natl Acad Sci USA 91, 8641 8645.
15. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, Smolenski A, Lohmann SM & Wollert KC (2006). cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 281, 32831 32840.
16. Fischmeister R, Castro L, Abi-Gerges A, Rochais F & Vandecasteele G (2005). Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 142, 136 143.
17. Flesch M, Margulies KB, Mochmann HC, Engel D, Sivasubramanian N & Mann DL (2001). Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation 104, 2273 2276.
18. Friebe A & Koesling D (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93, 96 105.
19. Garreffa AM, Woodman OL, Cao AH & Ritchie RH (2006). Sodium nitroprusside protects adult rat cardiac myocytes from cellular injury induced by simulated ischemia: role for a non-cGMP-dependent mechanism of nitric oxide protection. J Cardiovasc Pharmacol 47, 1 8.
20. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K & Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48, 184 188.
21. Gaston BM, Carver J, Doctor A & Palmer LA (2003). S-Nitrosylation signaling in cell biology. Mol Interventions 3, 253 263.
22. Han J, Lee JD, Bibbs L & Ulevitch RJ (1994). A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808 811.
23. He Z, Cho YY, Liu G, Ma WY, Bode AM & Dong Z (2003). p38 Mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor. J Biol Chem 278, 26435 26442.
24. Hochman JS (2003). Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107, 2998 3002.
25. Hofmann F (2005). The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280, 1 4.
26. Johnson GL & Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911 1912.
27. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF & Molkentin JD (2004). Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279, 15524 15530.
28. Kavurma MM & Khachigian LM (2003). ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 89, 289 300.
29. V1.2a,b) by protein kinases. Am J Physiol Cell Physiol 281, C1743 C1756.
30. Klassen SS & Rabkin SW (2007). The role of p53 in nitric oxide-induced cardiomyocyte cell death. DNA Cell Biol 26, 465 475.
31. Kong JY, Klassen SS & Rabkin SW (2005). Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: a potential mechanism for loss of mitochondrial transmembrane potential and apoptosis. Mol Cell Biochem 278, 39 51.
32. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC & Young PR (1997). Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235, 533 538.
33. Kyoi S, Otani H, Matsuhisa S, Akita Y, Tatsumi K, Enoki C, Fujiwara H, Imamura H, Kamihata H & Iwasaka T (2006). Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res 69, 888 898.
34. Kyriakis JM & Avruch J (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81, 807 869.
35. Layland J, Li JM & Shah AM (2002). Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol 540, 457 467.
36. Lee MH, Jang MH, Kim EK, Han SW, Cho SY & Kim CJ (2005). Nitric oxide induces apoptosis in mouse C2C12 myoblast cells. J Pharmacol Sci 97, 369 376.
37. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G & Vlahos CJ (2001). Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK α is the predominant isoform expressed in human heart. J Mol Cell Cardiol 33, 1527 1540.
38. Li G, Xiao Y & Zhang L (2005). Cocaine induces apoptosis in fetal rat myocardial cells through the p38 mitogen-activated protein kinase and mitochondrial/cytochrome c pathways. J Pharmacol Exp Ther 312, 112 119.
39. Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G & Protter AA (2006). Selective inhibition of p38α MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 291, H1972 H1977.
40. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA & Molkentin JD (2004). MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109, 1938 1941.
41. Lou H, Danelisen I & Singal PK (2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 288, H1925 H1930.
42. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ & Yue TL (1999). Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99, 1685 1691.
43. MacKenzie IM, Garrard CS & Young JD (2001). Indices of nitric oxide synthesis and outcome in critically ill patients. Anaesthesia 56, 326 330.
44. Martin JL, Avkiran M, Quinlan RA, Cohen P & Marber MS (2001). Antiischemic effects of SB203580 are mediated through the inhibition of p38α mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 89, 750 752.
45. Mocanu MM, Baxter GF, Yue Y, Critz SD & Yellon DM (2000). The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol 95, 472 478.
46. Nagy N, Shiroto K, Malik G, Huang CK, Gaestel M, Abdellatif M, Tosaki A, Maulik N & Das DK (2007). Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol 42, 981 990.
47. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV & Critz SD (2000). Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res 86, 144 151.
48. Okada T, Otani H, Wu Y, Kyoi S, Enoki C, Fujiwara H, Sumida T, Hattori R & Imamura H (2005). Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation. Am J Physiol Heart Circ Physiol 289, H2310 H2318.
49. Padgett CM & Whorton AR (1998). Cellular responses to nitric oxide: role of protein S-thiolation/dethiolation. Arch Biochem Biophys 358, 232 242.
50. Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY & Teng CM (2004). YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc Res 61, 152 158.
51. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K & Cobb MH (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine Rev 22, 153 183.
52. 1-adrenergic receptor. J Clin Invest 117, 1335 1343.
53. Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, Benito M & Nebreda AR (2004). p38α Mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 15, 922 933.
54. Rabkin SW (2002). Fumonisin blunts nitric oxide-induced and nitroprusside-induced cardiomyocyte death. Nitric Oxide 7, 229 235.
55. Rabkin SW, Klassen SS & Tsang MY (2007). Sodium nitroprusside activates p38 mitogen activated protein kinase through a cGMP/PKG independent mechanism. Life Sci 81, 640 646.
56. Rabkin SW & Kong JY (2000). Nitroprusside induces cardiomyocyte death: interaction with hydrogen peroxide. Am J Physiol Heart Circ Physiol 279, H3089 H3100.
57. Rabkin SW, Ohmae M & Klass DJ (1982). Antiarrhythmic effects of cyclic guanosine 3′:5′-monophosphate and sodium nitroprusside on barium chloride arrhythmias in rabbits. Arch Pharmacodyn Ther 257, 225 238.
58. Rakhit RD, Kabir AN, Mockridge JW, Saurin A & Marber MS (2001). Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. Biochem Biophys Res Commun 286, 995 1002.
59. Rao DN, Elguindi S & O'Brien PJ (1991). Reductive metabolism of nitroprusside in rat hepatocytes and human erythrocytes. Arch Biochem Biophys 286, 30 37.
60. Satoh S & Makino N (2001). Intracellular mechanisms of cGMP-mediated regulation of myocardial contraction. Basic Res Cardiol 96, 652 658.
61. Schmidt HH, Lohmann SM & Walter U (1993). The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1178, 153 175.
62. Schneider S, Chen W, Hou J, Steenbergen C & Murphy E (2001). Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol 280, H499 508.
63. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S & Krum H (2004). p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44, 1679 1689.
64. Stefanelli C, Pignatti C, Tantini B, Stanic I, Bonavita F, Muscari C, Guarnieri C, Clo C & Caldarera CM (1999). Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes. Biochim Biophys Acta 1450, 406 413.
65. Storling J, Binzer J, Andersson AK, Zullig RA, Tonnesen M, Lehmann R, Spinas GA, Sandler S, Billestrup N & Mandrup-Poulsen T (2005). Nitric oxide contributes to cytokine-induced apoptosis in pancreatic β cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 48, 2039 2050.
66. Strand OA, Leone A, Giercksky KE & Kirkeboen KA (2000). Nitric oxide indices in human septic shock. Crit Care Med 28, 2779 2785.
67. Taimor G, Rakow A & Piper HM (2001). Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes. FASEB J 15, 2518 2520.
68. Terwel D, Nieland LJ, Schutte B, Reutelingsperger CP, Ramaekers FC & Steinbusch HW (2000). S-Nitroso-N-acetylpenicillamine and nitroprusside induce apoptosis in a neuronal cell line by the production of different reactive molecules. Eur J Pharmacol 400, 19 33.
69. Vaandrager AB & de Jonge HR (1996). Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 157, 23 30.
70. Vila-Petroff MG, Younes A, Egan J, Lakatta EG & Sollott SJ (1999). Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84, 1020 1031.
71. Waldman SA & Murad F (1987). Cyclic GMP synthesis and function. Pharmacol Rev 39, 163 196.
72. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL & Lee JC (1997). Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272, 12116 12121.